Claims for Patent: 7,303,746
✉ Email this page to a colleague
Summary for Patent: 7,303,746
Title: | Methods of treating eye disorders with modified chimeric polypeptides |
Abstract: | Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy. |
Inventor(s): | Wiegand; Stanley J. (Croton on Hudson, NY), Papadopoulos; Nicholas (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) |
Application Number: | 10/988,243 |
Patent Claims: | 1. A method of treating retinal neovascularization, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient in need
thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16.
2. The method of claim 1, wherein neovascularization is induced by ischemia. 3. A method of treating, ameliorating, or inhibiting choroidal neovascularization, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGE) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16. 4. A method of treating, ameliorating, or inhibiting vascular leak in the retina, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16. 5. A method of treating, ameliorating, or inhibiting retinal edema, comprising administering a fusion polypeptide capable of binding vascular endothelial growth factor (VEGF) to a patient in need thereof, wherein the fusion polypeptide comprises the amino acid sequence of SEQ ID NO:16. |
Details for Patent 7,303,746
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | November 18, 2011 | ⤷ Sign Up | 2039-02-26 |
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | August 16, 2018 | ⤷ Sign Up | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,303,746
Country | Patent Number | Estimated Expiration |
---|---|---|
Argentina | 044938 | ⤷ Sign Up |
Austria | E293164 | ⤷ Sign Up |
Austria | E417928 | ⤷ Sign Up |
Austria | E427962 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.